National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Tixagevimab /cilgavimab (Evusheld®). HTA ID: 22015

Evusheld is indicated for the pre-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg.

 

NCPE Assessment Process Complete
Rapid review commissioned 09/03/2022
Rapid review completed 11/04/2022
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tixagevimab/cilgavimab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by the HSE 29/04/2022
Pre-submission consultation with Applicant 29/06/2022
Full HTA submission received from Applicant 16/08/2022
Preliminary review sent to Applicant 28/10/2022
NCPE assessment re-commenced 28/11/2022
Factual accuracy check sent to Applicant 12/12/2022
NCPE assessment re-commenced 19/12/2022
NCPE assessment completed 21/12/2022
NCPE assessment outcome The NCPE recommends that tixagevimab/cilgavimab not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.